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ABSTRACT 
Introduction: Beta-thalassemia is one of the most prevalent inherited blood diseases among Iranians. The 
aim of this study was to elucidate the chromosomal background of beta-thalassemia mutations in Esfahan 
province, Iran. 
Materials and Methods: In this study, we investigated three frequent mutations (c.315+1G>A, c.93-21G>A 
and c.92+5G>C in β-globin gene, the frequency of RFLP haplotypes, and LD between markers at β-globin 
gene cluster) in 150 beta-thalassemia patients and 50 healthy individuals. The molecular and population 
genetic investigations were performed on RFLP markers HindIII in the c.315+1G>A of Gγ (HindIIIG) and Aγ 
(HindIIIA) genes, AvaII in the c.315+1G>A of β-globin gene and BamHI 3' to the β-globin gene. All statistical 
analyses were performed using Power Marker software and SISA server.  
Results: Fifty percent of beta-thalasemia patients were associated with these mutations. Haplotype I was the 
most prevalent haplotype among beta-thalassemia patients (39.33%) and normal individuals (46%). The 
commonest c.315+1G>A mutation in our population was tightly linked with haplotype III (43.75%) and 
haplotype I (31.25%). The second prevalent mutation, c.92+5G>C, was 90%, 6.66%, and 3.33% in linkage 
disequilibrium with haplotypes I, VII, and III, respectively. The c.93-21G>A mutation indicated a strong 
association with haplotype I (80%).  
Conclusion: Our study participants like beta-thalassemia patients from Kermanshah province was found to 
possess a similar haplotype background for common mutations. The emergence of most prevalent mutations 
on chromosomes with different haplotypes can be explained by gene conversion and recombination. High 
linkage of a mutation with specific haplotype is consistent with the hypothesis that chromosomes carrying 
beta-thalassemia mutations experienced positive selection pressure, probably because of the protection 
against malaria experienced by beta-thalassemia carriers. 
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  Thalassemia patients comprise approximately 5% 
of global population. The gene frequency of beta 
thalassemia is high in Iran and varies in different 
regions of the country1. In Isfahan, located around 
Zayanderud, its frequency has been estimated up to 
approximately 8%2. Clinical complications and 
mental difficulties which are prevalent in 
thalassemia patients, the costs expended to treat 
these patients, and high frequency of beta- 
thalassemia gene in Isfahan highlight the necessity 
of further research2,3. The use of genetic markers 
may be beneficial when mutation is undetected4. 
Sequencing and direct detection of mutations is a 
time-consuming process due to the large number of 
known mutations and potential new mutations in 
the β-globin gene. Therefore, alternative methods 
of genetic diagnosis are according to linkage studies 
by means of polymorphic markers linked to the β-
globin gene region5. Although markers could be 
independently investigated, analysis of markers as 
haplotypes is empirically more informative. The 
haplotypes with 5% or higher frequency are 
considered as population-identifying6. In some 
subpopulations, a limited number of RFLP-
haplotypes of β-globin gene cluster has indicated 
non-random association (high linkage) with specific 
beta -thalassemia mutations7,8. Analysis of beta 
haplotype is useful for identification of new 
mutations in β-globin gene, prenatal diagnosis, and 
epidemiological studies. Also, it should be 
extensively done to detect the mechanism and 
origin of beta-thalassemia mutations and to 
implement novel diagnostic and therapeutic 
strategies9. Prenatal diagnosis of β-globin gene 
disorders using molecular markers depends on 
linkage disequilibrium in the β-globin gene 
mutations and the adjacent markers. Failure to 
consider this could lead to error in diagnosis. 
Recombination hot spots reduce linkage 
disequilibrium and breakdown in the pattern of 
haplotype blocks in the short distances as much as 
1-2 kb. The β-globin gene cluster contains one of 
the first known hot spots in humans10. Therefore, it 
is necessary to measure the LD between the used 
markers alongside the estimation of haplotype 
frequency in a population. 
Iran’s population consists of various 
subpopulations, and therefore each region could 
have an independent set of mutations and 
haplotypes. To the best of our knowledge, no study 
has been yet conducted to investigate the 
association of the haplotypes with beta thalassemia 
mutations in Isfahan. The present study was 
conducted to determine the frequency of HindIIIA- 
HindIIIG- AvaII- BamHI haplotypes and their 
association with the three prevalent beta- 
thalassemia mutations among the population of 
Isfahan Province. 
 
MATERIALS AND METHODS  
Study population 
The patient group consisted of 150 unrelated beta-
thalassemia major patients who referred to the 
Thalassemia Ward of Seyed al-Shohada Hospital of 
Isfahan. The control group included 50 healthy 
individuals from the same area. The necessary data, 
including demographic characteristics, family 
history and hemoglobin level (from electrophoresis 
results in patients’ medical file) were recorded in a 
questionnaire, and blood samples were taken with 
the patients’ consent. The exclusion criteria 
included patients with other anemia due to other 
causes. 
Β- globin genotyping and haplotyping 
Blood samples were collected in sterile tubes 
containing EDTA, and DNA was extracted from 
whole blood using salting out method11. Quality of 
extracted DNA was evaluated according to 260/280 
absorbance ratio, measured by Nano Drop 
spectrometer (Thermo Scientific, Waltham, MA, 
USA). Afterward, prevalent mutations, c.315+1G>A; 
c.92+5G>C; c.93-21G>A, were investigated by 
ARMS-PCR using primers in Old study12. For analysis 
of haplotype markers [HindIII in the c.315+1G>A of 
Gγ (HindIIIG) and Aγ (HindIIIA) genes, AvaII in 
c.315+1G>A of the he β-globin gene and BamHI 3' 
to the β-globin gene], a part of genomic DNA 
containing the fragment of interest was amplified 
by PCR and digested with the appropriate 
restriction enzyme. The primers used in this study 












All statistical analyses were performed by Power 




In the present study, three prevalent mutations 
c.315+1G>A, c.93-21G>A and c.92+5G>C were 
screened in 150 beta-thalassemia patients. Sixty of 
150 patients were associated with mentioned 
mutations. The frequencies of mutations are shown 
in Table1. 
 
Table 1. Frequency of mutations 
Mutation Number patients (%) 
c.315+1G>A / c.315+1G>A               40 (26.66%) 
c.92+5G>C / c.92+5G>C               15 (10%) 
c.93-21G>A / c.93-21G>A               5 (3.33%) 
Total                     60 
 
Β-globin haplotype 
Haplotype analysis was performed in 150 beta- 
thalassemia carriers and 50 healthy individuals 
using Power Marker software, and 6 different 
haplotypes were identified. Orkin et al’s naming of 
the haplotypes was used in the present study. The 
results of the β-globin gene cluster haplotype 
analysis are shown in Figures 1 and 2.  
As shown in Table 2, haplotype I was the most 
prevalent haplotype followed by haplotypes III, VII 
and II among healthy and beta-thalassemia 
chromosomes with the frequency of 46% vs. 
39.33%, 26% vs. 32.66%, 16.66% vs. 18.33% and 3% 
vs. 8.33%, respectively. Overall, haplotypes I and III 
comprised 70% of the haplotypes. Haplotypes I, III 
and VII as well as haplotype II (8.3%) with over 5% 
frequency in beta-thalassemia chromosomes could 
be considered as identifying haplotypes in the 
population (Table 2). The most prevalent mutation, 
c.315+1G>A, in Isfahan province exhibited 43.75% 
in linkage with haplotype III and 31.23% with 
haplotype I, while haplotypes III and I were 26% and 
46% linkage with healthy chromosomes, 
respectively. Interestingly, the most prevalent 
mutation (c.315+1G>A) in both most prevalent 
haplotypes (I and III) was the most frequent. 
c.315+1G>A was also linked with haplotypes IV and 
VII but less than the first two haplotypes. 
c.92+5G>C mutation was in linkage with haplotype I 
(90%), haplotype VII (6.66%) and haplotype III 
(3.33%). Also c.93-21G>A exhibited 80% in linkage 





Figure 1. HindIII PCR–RFLP products on agarose gel. A. HindIIIA. L1 and 
L2 showing the undigested samples, L3 showing the heterozygosity and 
L4 showing the homozygousity. L5 is 1000 bp DNA ladder. For 
homozygous individuals (-/-) two undigested band (933 bp and 109 bp) 
were visible. Four digested bands (933 bp, 681 bp, 252 bp and 109 bp) 
were seen in heterozygous individuals, whereas for homozygous 
patients (+/+) three digested bands (681 bp, 252 bp and 109 bp) were 
detected. B. HindIIIG. L1 showing the homozygousity, L2 showing the 
undigested sample, and L3 and L4 showing the heterozygosity. L 5 is 
1000 bp DNA ladder. For homozygous individuals (-/-) two undigested 
band (970 bp and 232 bp) were visible. Four digested bands (970 bp, 
697 bp, 273 bp and 232 bp) were seen in heterozygous individuals, 
whereas for homozygous patients (+/+) three digested bands (697 bp, 
273 bp and 232 bp) were detected. 
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Figure 2. AvaII and BamHI PCR–RFLP products on agarose gel. A. AvaII. 
L1 and L3 showing homozygousity, L2 showing the heterozygosity and 
L4 showing the undigested sample. L5 is 1000 bp DNA ladder. For 
homozygous individuals one undigested band (963 bp) was visible. 
Three digested bands (963 bp, 772 bp, and 191 bp) were seen in 
heterozygous individuals, whereas for homozygous patients (+/+) two 
digested bands (772 bp, and 191 bp) were detected. B. BamHI. L1 
showing the homozygousity, L2 showing the heterozygosity. L7 showing 
undigested sample. L5 is 1000 bp DNA ladder. For homozygous 
individuals (-/-), one undigested band (1520 bp) was visible. Three 
digested bands (1520 bp, 1228 bp, and 292 bp) were seen in 
heterozygous individuals, whereas for homozygous patients (+/+) two 









Table 2. Comparison of frequency of haplotypes between healthy and 
Beta-thalasemia chromosomes 
βthal Frequency βA 
Frequency 
Haplotype Name 
  39.33% 46.0%  + +- -  I 
32.66% 26.0% -  + +-  III 
18.33% 16.66%  +- - -  VII 
3% 8.33% + + + + II 
5% 1.6%  +- + +  VI 
1.6% 0 - -  +-  IV 
300 100  Total 
(chromosome) 
 
Table 3. Haplotype frequency of three prevalent mutations 
IVS-I-110 (G:A) IVS-I-5 (G:C) IVS-II-I (G:A) Haplotype Name 
20% 3.33% 43.75 -  + +-  III 
80% 90% 31.25  + +- -  I 
0 6.66% 20  +- - -  VII 
0 0 5 - -  +-  IV 




After polymorphic markers were genotyped in the 
studied population, linkage disequilibrium was 
assessed by Power Marker software. The presence 
of mutant alleles in the studied population was 
thought to falsely cause an increase in the 
calculated LD between the markers. To remove this 
problem, D' and P-value were calculated for 
chromosomes of 50 healthy individuals. As shown in 
Table 4, D' was 0.8869 (P=0) between HindIIIG and 
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Table 4. Calculation of D' and Fisher's exact test P value by Power 
Marker software 
p-value D' Marker 2 Marker 1 
0.0 0.8869 HindIIIG HindIIIA 
0.267 0.2704 AvaII HindIIIA 
0.2 0.106  AvaII HindIIIG 
0.68 0.0283 BamHI HindIIIA 
0.9 0.0032 BamHI HindIIIG 
0.0 0.64 AvaII BamHI 
 
DISCUSSION 
   Beta-thalassemia is one of the most common 
inherited blood diseases in Iran. The objective of 
this study was to evaluate the β-globin gene cluster 
haplotypes of the beta-thalassemia mutations in 
Esfahan province. In the present study, the three 
common beta-thalassemia mutations among 150 
Iranian patients with beta-thalassemia have been 
characterized. The most common mutation was 
c.315+1G>A (26.66%), followed by c.92+5G>C (10%) 
and c.93-21G>A (3.33%). The c.315+1G>A mutation 
was found to be the most frequent mutation in the 
Kurdistan, Azarbayjan-Sharghi, and Fars provinces 
of Iran as well as most of the Arab countries 14-16. 
In haplotype analysis, we identified 6 different 
haplotypes that haplotype I was the most prevalent 
haplotype (46%), followed by haplotypes III (26%), 
VII (16.66%), II (8.33%), and VII (1.6%) in 
chromosomes of beta-thalassemia patients. 
Consistent with our results, Rahimi's report in the 
western of Iran confirmed that haplotype I was the 
most frequent haplotype among beta thalassemia 
major individuals and normal controls (35.7% and 
42.9%, respectively), followed by haplotype III 
(28.6%) in beta-thalassemia patients12. Similarly, 
haplotype I was the most frequent haplotype 
among beta-thalassemia patients from 
Mediterranean area17. Haplotypes I, II and III were 
also the most common in Italy, Greece, India and 
Turkey18. In Fars Province, haplotype I was derived 
as the most frequent haplotype, followed by 
haplotypes V and III in beta-thalassemia carriers and 
healthy individuals with a frequency of 46.2% vs. 
43%, 15.4% vs. 3.8% and 7.7% vs. 15.4%, 
respectively19. Since Haplotype I is the most 
frequent haplotype among beta-thalasemia patients 
and healthy individuals, it implies that beta- 
thalassemia mutations could have arisen from 
common chromosomal backgrounds in the 
population. However, this could be partially 
explained by selection pressure or gene flow1.  
The strong linkage disequilibrium of beta gene 
cluster haplotypes with prevalent mutations has 
been reported previously20-22. In our population, 
c.315+1G>A mutation is in linkage disequilibrium 
with haplotypes III (43.75%), I (31.25%), VII (20%), 
and IV (5%), respectively. It can be suggested that 
the high frequency of the c.315+1G>A mutation 
resulted in the high prevalence of haplotype III in 
our study. Rahimi et al.’s report in Kermanshah 
province has indicated that c.315+1G>A mutation 
was tightly linked with haplotype III which is in line 
with our results, representing the same origin of 
this mutation in two regions12. 
Conversely, this mutation was linked to haplotypes I 
and III in Hormozgan and Fars provinces19. Mansoori 
et al. have shown that this mutation was 
predominantly associated with haplotype IV in 
Azarbayjan-Sharghi province16. The association of 
this mutation with haplotypes III and V among the 
Turkish population 23 and with haplotypes I and III 
among the Palestinian 24 and Lebanese 25 
populations have been reported, respectively. 
The mutation c.92+5G>C was firstly reported from 
China and India and is the most prevalent mutation 
in the UAE. However, this mutation in the Arab 
population is found on a haplotype of β-globin 
which is different from that in India and hence is 
thought to have a different origin15. In Brazil, 
c.92+5G>C is linked with haplotypes I and V26. Most 
alleles of Indian with this mutation have haplotype 
VII27. In Kermanshah population, this mutation was 
tightly linked with c.315+1G>A (100%) 12. In the 
present study, c.92+5G>C mutation indicates a 
strong association with haplotypes I (90%) and a 
weak association with haplotypes VII (6.66%) and III 
(3.33%), respectively. Moreover, c.93-21G>A 
mutation was 80% and 20% in linkage 
disequilibrium with haplotypes, I and III, 
respectively. In Kermanshah province, c.93-21G>A 
mutation was found to be linked to haplotypes I, IX, 
A and atypical12. Previous studies show that this 
mutation is associated with haplotype I in Lebanon, 
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Jewish, Turkey and Algeria populations 28-30, and 
with haplotypes XIII and I in Mediterranean 
region17. 
Calculation of LD among the markers demonstrated 
that between the markers of 5', i.e., HindIIIA and 
HindIIIG, there was linkage disequilibrium, but these 
markers did not have linkage disequilibrium with 
any markers of 3'. Besides, there was a high linkage 
between markers of 3', i.e., BamHI and AvaII 
(D'=0.64, p=0). These findings indicate that 
recombination hotspot is located somewhere 
between these two classes of markers, causing 
separation of linkage between them. In this report, 
the presence of hotspot and lack of LD among sub- 
haplotypes 5' and 3' were confirmed. These findings 
are consistent with Rahimi et al. study in 
Kermanshah, western of Iran12, Yavarian et al. study 
in Hormozgan, south of Iran 31, Rahimi et al. study in 
Fars, southwestern of Iran32. Moreover, the 
presence of hotspot and lack of LD among sub- 
haplotypes 5' and 3' have been confirmed in many 
studies worldwide. The rate and pattern of LD vary 
in different populations, which relate to the factors 
associated with genetic drift, migration and so on. 
The emergence of most common mutations on 
chromosomes with different haplotypes can be 
explained by gene conversion and recombination12. 
However, all mutations are created on the same 
healthy chromosomal area. It follows that the most 
prevalent haplotypes in patients and healthy 
individuals are the same. This argument implies that 
the chromosomes with beta-thalassemia mutations 
have a positive selection pressure which is tolerated 
by carriers probably because of protection against 
malaria. The wide variety of haplotypes linked with 
a common mutation most probably represents that 
the mutation of interest is one of the oldest 
mutations of the area with adequate time for 
recombination or the mutation has been created 
independently on several haplotype areas. The 
linkage of the haplotype with the mutation is 
virtually similar in different areas, contradicting the 
mutations' independent development on several 
haplotype areas. The creation of multiple haplotype 
linkages with the mutation may simply be due to 
gene conversion events in globin genes. The present 
study is consistent with Rahimi et al. study in 
Kermanshah12, potentially indicating the same 
origin of these mutations in the two regions.  
 
CONCLUSION 
   In this study, we first reported β-globin gene 
cluster haplotypes association with a common 
mutation in Esfahan province in Iran. Our study 
participants like beta-thalassemia patients from 
Kermanshah province was found to possess a 
similar haplotype background for common 
mutations. Identification of the most prevalent 
mutations on different haplotype backgrounds can 
be explained by a variety of gene conversion and 
recombination events. High linkage of a mutation 
with specific haplotype is consistent with the 
hypothesis that chromosomes carrying beta- 
thalassemia mutations experienced positive 
selection pressure, probably because of the 
protection against malaria experienced by beta- 
thalassemia carriers. 
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